Bellerophon Therapeutics (BLPH) Stock

Bellerophon Therapeutics (NASDAQ: BLPH ) stock is losing value on Tuesday after the clinical-stage therapeutics company was sent a delisting notice. The Listing Qualifications Department for the Nasdaq Exchange has decided to delist shares of BLPH stock come Friday unless it requests a meeting with the Nasdaq Hearings Panel.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Bellerophon's (BLPH) shares fall as a late-stage study of INOpulse to treat fibrotic interstitial lung disease fails to meet its primary endpoint.

Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Shares of Bellerophon Therapeutics Inc. BLPH, -83.00% plummeted 83% toward a record one-day decline, after the biotherapeutics company said its lung-disease treatment failed to meet its primary endpoint in a Phase 3 “Rebuild” study. The company said its INOpulse for the treatment of fibrotic Interstitial Lung Disease (fILD) performed worse than placebo, while the secondary endpoints demonstrated “minimal difference” between studied groups, with none approaching statistical significance.

Bellerophon Therapeutics (NASDAQ: BLPH ) stock is taking a massive beating on Monday after the pharmaceutical company posted poor clinical trial results. The bad news for BLPH stock comes from its Phase 3 clinical trial of INOpulse as a treatment for fibrotic Interstitial Lung Disease (fILD).

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are BLPH, CRD.B, REPX, HROW and LNTH.